SAB Biotherapeutics’ SAB-176 Receives US FDA’s Fast Track Designation for the Treatment of Type A and Type B Influenza
Shots:
- The US FDA has granted FTD to SAB-176 for high-risk patients with Type A & B influenza illness incl. those who have anti-viral resistant strains
- A no. of clinical & pre-clinical studies has been conducted on SAB-176, incl. a P-I trial in healthy volunteers & a P-IIa challenge study. The results suggest that SAB-176 provides broad Ab protection against a variety of strains of this rapidly mutating virus & the P-IIa study demonstrated extensive cross-protection, incl. strains not specifically targeted in the manufacturing of the therapies
- The company also received regulatory support from the US FDA & advance SAB-176 into the next phase of development incl. a P-IIb trial study design
Ref: Globe Newswire | Image: SAB Biotherapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
